Also, considering risks of arterial constriction, hypertension, and renal toxicity that may develop with supra therapeutic concentrations of TAC, dose adjustment based on observed serum concentrations should be made for intermediate (CYP3A5*1/*3) or rapid (CYP3A5*1/*1) metabolizers using TDM. This evidence concerns the gene CYP3A5 and hypertensive disorder.